Genital Warts Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Funding
• Alerts
• Clinical Trials
• Forums

A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine
Condition:   Human Papilloma Virus Infection Interventions:   Biological: Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli);   Biological: Recombinant Quadrivalent Human Papillomavirus (Types 6,11,16,18) Vaccine (Saccharomyces cerevisiae) Sponsors:   Beijing Health Guard Biotechnology, Inc;   Jiangsu Province Centers for Disease Control and Prevention;   National Institutes for Food and Drug Control, China;   Nanjing Sangruisi pharmtech Ltd.;   Shanghai Canming pharmtech Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 23, 2023 Category: Research Source Type: clinical trials